Explore Stanford technologies available for licensing:

Researchers at Stanford have developed compounds for inhibiting the epidermal growth factor receptor (EGFR) that covalently label a nucleophile that has not been targeted before.

Researchers at Stanford have developed a novel method of using macrocyclic compounds that act as inhibitors of epidermal growth factor receptor (EGFR) for the treatment or prevention of kinase-mediated disorders, including cancer and other proliferation diseases.